FEATURES OF COVID-19-ASSOCIATED PNEUMONIA IN UNVACCINATED PATIENTS WITH ARTERIAL HYPERTENSION
Keywords:coronavirus disease, COVID-19, hypertension, mortality, comorbidity.
Coronavirus disease 2019(COVID-19) is an important medical and social problem. Comorbidities may aggravate the clinical course of COVID-19 and increase mortality. The aimof this study was to investigate the clinical course of the COVID-19 in patients withstages IІ and III hypertension. 135 unvaccinated patients hospitalized for the COVID-19complicated by pneumonia were examined. The patients included in the study were divided into 2 groups: the main group (106 patients with hypertension) and the control group (29 patients without hypertension). In the main group, 11.3% of patients died, and in the control group, 6.9% of patients died. The mean age of the dead patients of both groups was higher than the mean age of the survivors (p = 0.035). It was found that patients with diabetes mellitus had a higher mortality rate than patients who did not have diabetes mellitus (RR= 2.96 [1.01–8.67], p = 0.047). Also, in the main group, the body mass index in patients who died was higher than in survivors (p = 0.02). Creatinine level at the time of discharge was higher in the main group (97.8 ± 4.0 μmol/L) than in the control group (84.2 ± 6.2 μmol/L) (p = 0.008). So, the lethality rate due to COVID-19 complicated by pneumonia in unvaccinated inpatients was 10.4%. Increased body mass index, diabetes mellitus, and old age are risk factors for death from the COVID-19 complicated by pneumonia.
Коронавірус (COVID-19). [online] Available at: <https://news.google.com/covid19/map?hl=uk&mid=%2Fm%2F02j71&gl=UA&ceid=UA%3Auk> [Accessed 1 April 2022].
WHO Director-General's opening remarks at the media briefing on CO-VID-19 - 3 March 2020. [online] Available at: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020> [Accessed 2 April 2022].
Raveendran A.V., Jayadevan R, Sashidharan S. Long COVID: An over-view. Diabetes Metab Syndr. 2021 May-Jun;15(3):869-875. doi: 10.1016/j.dsx.2021.04.007.
Ghaffari Darab M, Keshavarz K, Sadeghi E, Shahmohamadi J, Kavosi Z. The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran. BMC Health Serv Res. 2021 Dec;21(1): 132. doi: 10.1186/s12913-021-06126-8.
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020 Aug;2(8):1069-76. doi: 10.1007/s42399-020-00363-4.
Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a sys-tematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021 Dec;21(1):855. doi:10.1186/s12879-021-06536-3.
WHO.int. 2022. Hypertension. [online] Available at: <https://www.who.int/health-topics/hypertension/#tab=tab_1> [Accessed 3 April 2022].
Buford TW. Hypertension and aging. Ageing Res Rev. 2016 Mar;26:96-111. doi: 10.1016/j.arr.2016.01.007.